Leflunomide: benefits in RA still apparent at 2 years

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1266, 2000-01, pp. : 15-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

RA: leflunomide more costly than methotrexate

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 350, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Leflunomide: new data highlights long-term efficacy in RA

Inpharma, Vol. 1, Iss. 1222, 2000-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Rituximab benefits difficult-to-treat patients with RA

Inpharma, Vol. 1, Iss. 1523, 2006-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Infliximab enhances methotrexate benefits in early RA

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Leflunomide: An Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing

By Alcorn Nicola Saunders Sarah Madhok Rajan

Drug Safety, Vol. 32, Iss. 12, 2009-12 ,pp. : 1123-1134

Adis International

Access to resources Recommend Favorite